FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
press_releaseUnited States·U.S. Food and Drug Administration·Wire Summary
The U.S. Food and Drug Administration today approved TREGZI, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
AI Business Impact
How does this affect your business?
Get an AI analysis of this article grounded in your jurisdictions, practice areas, and any policy documents you've uploaded to Wansom.